BioSpace News Archive

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company will be presenting at two upcoming scientific conferences in November 2022.

Flare Therapeutics today presented translational insights from a retrospective advanced urothelial cancer (UC) cohort in a poster titled, “Peroxisome Proliferator-Activated Receptor Gamma (PPARG) status defines the luminal lineage in molecular profiles of advanced urothelial cancers (UC)” at the 34th EORTC-NCI-AACR Symposium.

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical devices and in vitro diagnostic technologies to the healthcare industry, today announced that fourth quarter and fiscal year 2022 financial results will be released before the market opens on Wednesday, November 9th.

SciSparc Ltd. announced that SciSparc Nutraceuticals Inc., its wholly owned subsidiary, has successfully launched a new keto gummies apple cider vinegar product under its brand Wellution™ on Amazon.com.

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a Biologics License Application (BLA) for ONS-5010 / LYTENAVA.

Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that on October 13, 2022, Health Canada authorized ACTEMRA® IV.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) has been recognized as the “Best Biotechnology Product” of 2022 by the Galien Foundation, which acknowledges extraordinary scientific innovations that improve the human condition.

Cigna health plans will be available on the individual marketplace for Indiana residents in eight counties, giving more people and communities access to affordable, predictable, and simple health care coverage in 2023.

The Biotechnology Innovation Organization and the Council of State Bioscience Associations released new data on the bioscience industry in the United States.

Hinova Pharmaceuticals Inc. (STAR: 688302) today presented their preclinical results of HP518, an orally bioavailable chimeric degrader targeting androgen receptor (AR) for prostate cancer treatment, at the 5th Annual TPD Summit.